eli lilly retatrutide clinical trials Phase 3 obesity trial results 2026 Starting Phase 3b Clinical Trial

State participation in the Medicaid Drug Rebate Program requires coverage of nearly all FDA-approved drugs for medically accepted indications, but weight-loss drugs are included in a small group of drugs that can be excluded from coverage

PloS Biol

Patients should inform the scheduling coordinator and procedural team about all medications, including GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists, with specific drug name, dose, and frequency

(August 2025)

Sometimes the switch itself introduces a new adjustment period with temporary worsening before improvement

The reduction held across every substance studied